Tesa/IPA Protocol
FDA APPROVAL PENDING
Limited Research
Growth
Tesa/IPA Protocol
35
Amino acids
Molecular weight
Blend
Type
The Tesa/IPA blend combines two complementary growth hormone secretagogues: Tesamorelin (a GHRH analog that stimulates GH release from the pituitary) and Ipamorelin (a selective ghrelin mimetic/GHRP that amplifies GH pulses). This combination addresses both the GHRH and GHRP pathways for synergistic GH release. Common formulations include 5mg/5mg (1:1 ratio) and 10mg/3mg (higher Tesamorelin) variants. Tesamorelin is FDA-approved for HIV-associated lipodystrophy, while Ipamorelin remains investigational.
Top researched benefits
Overview of Tesa/IPA Protocol
The blend leverages two distinct GH-releasing pathways: Tesamorelin is a synthetic GHRH analog that directly stimulates growth hormone-releasing hormone receptors on pituitary somatotrophs, triggering GH synthesis and secretion in a pulsatile, physiological manner. Ipamorelin is a selective ghrelin receptor (GHS-R1a) agonist that amplifies GH pulses without significantly affecting cortisol or prolactin. Together, they produce synergistic GH release greater than either compound alone, while maintaining the body's natural feedback mechanisms.
Body Composition
- Tesamorelin has demonstrated fat reduction in clinical trials; synergy with Ipamorelin may enhance effects.
- Tesamorelin specifically reduces visceral adipose tissue (FDA-approved indication).
- Enhanced GH promotes protein synthesis and lean tissue preservation.
Recovery And Wellness
- GH secretagogues often improve deep sleep quality.
- Enhanced GH supports tissue repair and recovery from exercise.
- Restoring more youthful GH levels may provide anti-aging benefits.
Metabolic Health
- Tesamorelin has shown improvements in lipid parameters in studies.
- Increased GH leads to increased IGF-1 production.
Storage
Reconstituted: 2-8°C, use within 4-6 weeks
Frequency
Once daily (evening preferred) or twice daily for advanced protocols
Typical Dose
200-500mcg total blend per injection
Cycle Duration
8-16 weeks continuous
Chemical Makeup
Key benefits
Synergistic GH release from dual pathways
More physiological pulsatile GH secretion
Tesamorelin's proven lipodystrophy benefits
Ipamorelin's clean side effect profile
Does not significantly affect cortisol or prolactin
Single injection convenience
May improve body composition, sleep, and recovery
Community interest
This peptide is still gaining traction in the community.
Tesamorelin + Ipamorelin GH Secretagogue Blend
This overview is informational and based on aggregated descriptions from studies and user reports.
Was it helpful?YesTesa/IPA Protocol Molecular Information
View the scientifc details of Tesa/IPA Protocol.
35
Amino Acids
Tesa/IPA Protocol
Thr
Thr
Position 1
Glu
Glu
Position 2
Ser
Ser
Position 3
Ala
Ala
Position 4
Met
Met
Position 5
Pyl
Pyl
Position 6
Arg
Arg
Position 7
Glu
Glu
Position 8
Leu
Leu
Position 9
Ile
Ile
Position 10
Asn
Asn
Position 11
Gly
Gly
Position 12
His
His
Position 13
Arg
Arg
Position 14
His
His
Position 15
Ala
Ala
Position 16
Asn
Asn
Position 17
Ala
Ala
Position 18
Leu
Leu
Position 19
Pyl
Pyl
Position 20
Gly
Gly
Position 21
Ile
Ile
Position 22
Pro
Pro
Position 23
Ala
Ala
Position 24
Met
Met
Position 25
Pyl
Pyl
Position 26
Arg
Arg
Position 27
Glu
Glu
Position 28
Leu
Leu
Position 29
Ile
Ile
Position 30
Asn
Asn
Position 31
Gly
Gly
Position 32
His
His
Position 33
Arg
Arg
Position 34
Pro
Pro
Position 35
Molecular Weight
0DaChain Length
35Amino AcidsType
BlendTesa/IPA Protocol Protocols
Subcutaneous injection, typically administered before bed or in the morning on an empty stomach. Evening dosing may enhance natural nighttime GH pulse. Avoid eating 2-3 hours before and 30-60 minutes after injection for optimal results.
| Goal | Dosage | Frequency | Route |
|---|---|---|---|
| Standard protocol (5/5 blend) | 200 | 1 week range | SubQ |
| Enhanced protocol (10/3 blend) | 300 | 1 week range | SubQ |
| Twice daily (advanced) | 200 | — | SubQ |
Reconstitution Instructions
Materials needed:
Steps to reconstitute
- Clean vial top with alcohol pad
- Add 2mL bacteriostatic water for convenient dosing
- Gently swirl - do not shake
- Solution should appear clear
- Label with date and concentration
- Store refrigerated immediately
- Use within 4-6 weeks
Tesa/IPA Protocol Cycle
The Tesa/IPA Protocol Cycle section explains how long a typical cycle lasts and what to expect during each phase. Over time, your body can become less responsive with continuous use.
Taking breaks between cycles may help maintain effectiveness and support better overall results.
- Week 1-2
- Improved sleep quality often noticed first; initial GH response
- Week 2-4
- Enhanced recovery; subtle body composition changes beginning
- Week 4-8
- Noticeable fat loss (especially visceral); improved energy
- Week 8-16
- Full body composition benefits; continued improvements
Dosing tools
Tesa/IPA Protocol Blend Calculator
Calculate peptide doses with our visual syringe guide.
0.3mL / 30 units
5 units
0.050 mL
1 mL
2 mL
3 mL
5 mL
Custom
Tesa/IPA Protocol Composition
(10mg vial)
Tesamorelin
5mg (50%)
Ipamorelin
5mg (50%)
Conversion: 1,000 mcg = 1 mg
Results
Safe concentration rangeConcentration
10.00
mg/mL
Doses per vial
20
Total blend to inject
0.50
mg
You'll get:
- Tesamorelin
- 250 mcgANCHOR
- Ipamorelin
- 250 mcg
How it works
Select a blend, enter how much water you added, then specify the dose you want of any single component. The calculator figures out how much total blend to inject and shows what you'll get of each peptide.
Dosing Guidance
Recommended Schedule
Once daily (evening preferred) or twice daily for advanced protocols
Supply Duration
This vial provides 20 doses (20-day supply at 250 mcg daily)
Research Purposes Only
These calculators are provided for educational and research purposes only. Always verify calculations and consult with qualified professionals. The information provided is not medical advice. Peptides should only be used in accordance with applicable laws and regulations.
Peptide Interactions
Research suggestions of Tesa/IPA Protocol interactions with other common peptides and substances.
Healing
bpc
Longevity
BPC-157
COMPATIBLE
Different mechanisms; can complement for healing with GH support.
Weight
mk6
Growth
MK-677
MONITOR
Both affect GH release; combination may be excessive and affect glucose.
Weight
sem
Metabolic
Semaglutide
COMPATIBLE
Different pathways; some combine for body composition goals.
Side effects
Monitor: Be careful when combining Tesa/IPA Protocol with MK-677.
Contraindications
Active malignancy (GH may promote tumor growth)
Diabetic retinopathy
Pregnancy or breastfeeding
Pituitary disorders
Hypersensitivity to components
Stop signs
Severe injection site reactions
Significant swelling or edema
Signs of glucose dysregulation
Severe joint pain
Allergic reactions
Bad signs
Comments
0.0
0 reviews
5
4
3
2
1
No comments yet
Be the first to share your experience. Your review helps others make more informed decisions.
Frequently asked questions
What benefits can peptides offer in research?
Peptides can support cellular repair, immune function, metabolic health, and tissue regeneration. Research suggests they may help with recovery, sleep quality, skin health, and cognitive function, depending on the specific peptide and its mechanism of action.
What are some exciting applications of peptides in modern science?
Current research explores peptides for longevity, muscle recovery, wound healing, metabolic disorders, and neuroprotection. Scientists are also investigating peptide-based drug delivery and targeted therapies that could offer more precise treatment options.
How do peptides influence health and wellness?
Peptides work by binding to receptors on cells and triggering specific biological responses. Depending on the peptide, they may promote growth hormone release, support collagen production, modulate inflammation, or influence neurotransmitter activity—each with different implications for health and wellness.
Where can I find the latest studies on peptide applications?
Peer-reviewed journals such as Nature, Science, and specialized publications like Peptides and the Journal of Peptide Science publish ongoing research. PubMed and Google Scholar are useful for searching studies by peptide name or condition.
Are there any guidelines for using peptides in research?
Research use of peptides typically follows institutional review board (IRB) protocols and regulatory guidelines. Dosage, administration route, and safety monitoring should align with published literature and applicable regulations in your jurisdiction.
What is the difference between peptides and proteins?
Peptides are short chains of amino acids (typically under 50), while proteins are longer chains that fold into complex structures. Peptides are often more stable, easier to synthesize, and can cross cell membranes more readily, making them attractive for therapeutic applications.
How should peptides be stored?
Most peptides require refrigeration (2–8°C) and protection from light. Reconstituted peptides often have shorter stability and may need to be used within days or weeks. Always follow the manufacturer's or research protocol's storage instructions.
Can peptides be taken orally?
Some peptides are bioavailable orally, but many are broken down by digestive enzymes before reaching the bloodstream. Subcutaneous injection, nasal administration, or other routes are often used in research to improve bioavailability. The optimal route depends on the specific peptide.
Tesa/IPA ProtocolResearch References
Tesa/IPA Protocol is a limited research compound
Tesa/IPA Protocol
Tesa/IPA Protocol is a limited research compound
Tesamorelin FDA Approval for HIV Lipodystrophy
Tesamorelin (Egrifta) approved for reduction of excess abdominal fat in HIV patients.
n.d.
Tesamorelin Effects on Visceral Fat
Tesamorelin significantly reduces visceral adipose tissue and improves lipid profiles.
n.d.
Ipamorelin Selectivity Profile
Ipamorelin selectively releases GH without affecting cortisol, prolactin, or ACTH.
n.d.
GHRH + GHRP Synergy
Combining GHRH and GHRP pathways produces synergistic GH release greater than either alone.
n.d.